Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX – CWEB.com
Institutional investors currently hold major shares in BioPharmX Corporation(BPMX) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018
BioPharmX Corporation (BPMX) stock was most active stock of Wall Street Market on Tuesday. BPMX moved -1.77% to 0.19. BPMX received interesting focus from Active Investors and it has been trading on front line as seeing to it recent volume.
Statistic show the size of the acne treatment market worldwide in 2016 and a forecast for 2025, in billion U.S. dollars. In 2016, the global acne treatment market was worth some 4.9 billion dollars and was expected to grow to over 7 billion by the end of 2025.
Statistic also show the market value of skincare products in Great Britain from 2009 to 2016. The total value of the skincare market in December 2016 was measured at approximately 2.16 billion British pounds
|Owner Name||Date||Shared Held||Change (Shares)||Change (%)||Value (in 1,000s)|
|VIVO CAPITAL, LLC||05/13/2018||16,128,515||2,328,571||16.87||3,306|
|FRANKLIN RESOURCES INC||05/13/2018||9,749,615||0||0.00||1,999|
|VANGUARD GROUP INC||05/13/2018||5,498,918||3,541,971||181.00||1,127|
|GEODE CAPITAL MANAGEMENT, LLC||03/31/2018||671,686||347,719||107.33||138|
|VIRTU FINANCIAL LLC||03/31/2018||426,837||426,837||New||88|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||03/31/2018||181,335||181,335||New||37|
|CITADEL ADVISORS LLC||03/31/2018||146,859||146,859||New||30|
|MCF ADVISORS LLC||03/31/2018||105,629||105,629||New||22|
|JANE STREET GROUP, LLC||03/31/2018||96,941||96,941||New||20|
|TWO SIGMA SECURITIES, LLC||03/31/2018||93,390||47,105||101.77||19|
|NORTHERN TRUST CORP||03/31/2018||92,518||0||0.00||19|
|UBS GROUP AG||03/31/2018||70,367||36,614||108.48||14|
|LADENBURG THALMANN FINANCIAL SERVICES INC.||03/31/2018||64,200||0||0.00||13|
|CREDIT SUISSE AG/||03/31/2018||50,000||50,000||New||10|
|Total Institutional Shares||27||33,878,519|
On April 26th, 2018, BioPharmX reports its results for the quarter and year ended January 31st, 2018. For Q4 FY18, total operating expenses were $3.6 million, and net loss was $3.8 million.
For FY18, total operating expenses were $16.7 million, and net loss was $16.6 million. As of January 31st, 2018, cash and cash equivalents were $7.6 million.
BioPharmX Corporation (BPMX) has been working on the following pipeline for new products and FDA approvals.
HYDROPHILIC TOPICAL SYSTEM
1 Patent Issued, 21 Pending
- Hydrophilic: non-occlusive, non-oily
- Non-lipophilic (oil-based)
- Suitable for APIs degraded in water
- Improves bioavailability
- Not a suspension
- Miscible w/ sebum
Higher penetration and targeted delivery
1 Patent Pending
- Proprietary cross-linked injectable delivery system
- Prolonged release of biologics and small to mid-sized molecules
Suitable for aesthetics
3 Patents Issued, 4 Pending
- Separates hydrophilic APIs from boundary layer
- Encapsulates between the hydrophilic and hydrophobic phases of emulsion
Emulsion feels smooth to the touch
1 Patent Allowed, 3 Pending
- Oral delivery of iodide and iodate
- Patented formulation stabilizes iodine
- Delivery to targeted mammary cells
- Apoptotic and anti-proliferative effects
Commercially available product since 2014
Women’s Health Asset for Strategic Partnerships
The patent (U.S. Patent No. 9,918,998), entitled “Pharmaceutical Tetracycline Composition For Dermatological Use,” covers a topical composition comprised of minocycline or another tetracycline-class drug and a method for making such compositions. The patent also covers treatments of dermatological inflammation or infection using a minocycline composition. Current formulations protected by the patent include BPX-01 for the treatment of acne and BPX-04 for the treatment of rosacea.
This is the fourth U.S. patent issuance BioPharmX (BPMX) has received. Three earlier-issued U.S. patents protect the company’s encapsulation delivery system, which can isolate the API. The most recent of these patents, U.S. Patent No. 9,901,586, entitled “Dosage Form Comprising an Active Ingredient and a Plurality of Solid Porous Microcarriers,” was granted Feb. 27.
The US 9,918,998 patent protects tetracycline-class products carried by BioPharmX’s innovative delivery system, which for the first time stabilizes and fully solubilizes these drugs to make them effective in a topical formulation. This includes products that use other tetracycline-class drugs as well as combination products that combine antibiotics with other drugs, for example retinoids.
“This patent protection is a significant milestone for BioPharmX,” said President and Co-founder Anja Krammer. “It recognizes that our development of a topical tetracycline-class drug, something that has eluded the pharmaceutical industry since minocycline was first commercially used in the 1970s, is truly unique.”
BioPharmX has successfully completed a phase 2b trial for BPX-01 for acne and is in phase 3 readiness. The company has reported positive interim results from a feasibility study for BPX-04 for rosacea and is preparing for a phase 2 trial.
The Industry Biotechnology & Medical Research also suggest that BioPharmX Corporation (BPMX) is currently the cheapest stock against major companies below:
|PTIE||Pain Therapeutics Inc Com New||4/23/18||10.15||30.46%|
|SNMX||Senomyx Inc Com||5/14/18||1.42||8.40%|
|VRTX||Vertex Pharmaceuticals Inc Com||5/13/18||157.24||0.81%|
|ARQL||Arqule Inc Com||5/18/18||3.39||0.00%|
|ICLR||Icon Plc Shs||5/21/18||125.74||0.00%|
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators also suggest that BioPharmX Corporation (BPMX) , is undervalued.
CWEB Analysts have Reiterate a Buy Rating for BioPharmX Corporation (BPMX) and a Price Target of $7 within 12 months.
A possible partnership or major investment for BioPharmX Corporation (BPMX) is strongly possible in this coming month by big pharmaceutical company.
Read Full Article and Videos CWEB.com – Trending News, Blog, Shopping